Evidence map›Paper›PMID 28265266›Full record

ArticleFrontiers in microbiology2017

HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus.

Dahlene N Fusco, Henry Pratt, Stephen Kandilas, Scarlett Se Yun Cheon, Wenyu Lin, D Alex Cronkite, Megha Basavappa, Kate L Jeffrey, Anthony Anselmo, Ruslan Sadreyev and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. HELZ2 RegulatesCirculation · 2026
    Article
  5. Article
  6. Article
  7. Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Dahlene N FuscoGastrointestinal Division, Department of Medicine, Massachusetts General HospitalBoston, MA, USA; Division of Infectious Diseases, Vaccine and Immunotherapy Center, Department of Medicine, Massachusetts General HospitalBoston, MA, USA; Laboratory for Systems Pharmacology, Harvard Medical SchoolBoston, MA, USA.
Henry PrattGastrointestinal Division, Department of Medicine, Massachusetts General Hospital Boston, MA, USA.
Stephen KandilasDivision of Infectious Diseases, Vaccine and Immunotherapy Center, Department of Medicine, Massachusetts General HospitalBoston, MA, USA; Department of Medicine, Athens University Medical SchoolAthens, Greece.
Scarlett Se Yun CheonDepartment of Biology, Wellesley College Wellesley, MA, USA.
Wenyu LinGastrointestinal Division, Department of Medicine, Massachusetts General Hospital Boston, MA, USA.
D Alex CronkiteGastrointestinal Division, Department of Medicine, Massachusetts General Hospital Boston, MA, USA.
Megha BasavappaGastrointestinal Division, Department of Medicine, Massachusetts General Hospital Boston, MA, USA.
Kate L JeffreyGastrointestinal Division, Department of Medicine, Massachusetts General Hospital Boston, MA, USA.
Anthony AnselmoDepartment of Molecular Biology, Massachusetts General Hospital Boston, MA, USA.
Ruslan SadreyevDepartment of Molecular Biology, Massachusetts General Hospital Boston, MA, USA.
Clarence YappLaboratory for Systems Pharmacology, Harvard Medical School Boston, MA, USA.
Xu ShiDivision of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center Boston, MA, USA.
John F O'SullivanDivision of Cardiology, Department of Medicine, Massachusetts General Hospital Boston, MA, USA.
Robert E GersztenDivision of Cardiology, Department of Medicine, Beth Israel Deaconess Medical CenterBoston, MA, USA; Division of Cardiology, Department of Medicine, Massachusetts General HospitalBoston, MA, USA.
Takuya TomaruDepartment of Medicine and Molecular Science, Gunma University Graduate School of Medicine Maebashi, Japan.
Satoshi YoshinoDepartment of Medicine and Molecular Science, Gunma University Graduate School of Medicine Maebashi, Japan.
Tetsurou SatohDepartment of Medicine and Molecular Science, Gunma University Graduate School of Medicine Maebashi, Japan.
Raymond T ChungGastrointestinal Division, Department of Medicine, Massachusetts General Hospital Boston, MA, USA.
Massachusetts General Hospital · USGunma University · JPBeth Israel Deaconess Medical Center · USCenter for Systems Biology · USHarvard University · USWellesley College · US

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Takara Leah Stanley · 1994 to 2026
$31.6M
TRANSLATIONAL PHARMACOLOGY COREP50GM107618 · NIGMS · HARVARD MEDICAL SCHOOL · PI GOLAN, DAVID E. · 2014 to 2018
$10.8M
Argonaute proteins in the mammalian antiviral responseR01AI107087 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JEFFREY, KATE LOUISA · 2014 to 2018
$2.2M
Patient-Oriented Research on Hepatitis in Special PopulationsK24DK078772 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2007 to 2016
$1.6M
Interferon Effector Gene Activation to Circumvent Viral ImpedanceK08AI108629 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FUSCO, DAHLENE NICOLE · 2014 to 2016
$559k
NIAID NIH HHS K08 AI108629NIAID NIH HHS R01 AI107087NIAID NIH HHS U19 AI082630NIDDK NIH HHS K24 DK078772NIDDK NIH HHS P30 DK040561NIDDK NIH HHS P30 DK043351NIGMS NIH HHS P50 GM107618
6 · The paper itself

Abstract

Flaviviral infections including dengue virus are an increasing clinical problem worldwide. Dengue infection triggers host production of the type 1 IFN, IFN alpha, one of the strongest and broadest acting antivirals known. However, dengue virus subverts host IFN signaling at early steps of IFN signal transduction. This subversion allows unbridled viral replication which subsequently triggers ongoing production of IFN which, again, is subverted. Identification of downstream IFN antiviral effectors will provide targets which could be activated to restore broad acting antiviral activity, stopping the signal to produce endogenous IFN at toxic levels. To this end, we performed a targeted functional genomic screen for IFN antiviral effector genes (IEGs), identifying 56 IEGs required for antiviral effects of IFN against fully infectious dengue virus. Dengue IEGs were enriched for genes encoding nuclear receptor interacting proteins, including HELZ2, MAP2K4, SLC27A2, HSP90AA1, and HSP90AB1. We focused on HELZ2 (Helicase With Zinc Finger 2), an IFN stimulated gene and IEG which encodes a promiscuous nuclear factor coactivator that exists in two isoforms. The two unique HELZ2 isoforms are both IFN responsive, contain ISRE elements, and gene products increase in the nucleus upon IFN stimulation. Chromatin immunoprecipitation-sequencing revealed that the HELZ2 complex interacts with triglyceride-regulator LMF1. Mass spectrometry revealed that HELZ2 knockdown cells are depleted of triglyceride subsets. We thus sought to determine whether HELZ2 interacts with a nuclear receptor known to regulate immune response and lipid metabolism, AHR, and identified HELZ2:AHR interactions via co-immunoprecipitation, found that AHR is a dengue IEG, and that an AHR ligand, FICZ, exhibits anti-dengue activity. Primary bone marrow derived macrophages from HELZ2 knockout mice, compared to wild type controls, exhibit enhanced dengue infectivity. Overall, these findings reveal that IFN antiviral response is mediated by HELZ2 transcriptional upregulation, enrichment of HELZ2 protein levels in the nucleus, and activation of a transcriptional program that appears to modulate intracellular lipid state. IEGs identified in this study may serve as both (1) potential targets for host directed antiviral design, downstream of the common flaviviral subversion point, as well as (2) possible biomarkers, whose variation, natural, or iatrogenic, could affect host response to viral infections.

Indexed as

genes that are required for IFN-mediated suppression of virusinterferoninterferon effector gene (IEG)

Identifiers

PMID28265266
PMCPMC5316548
OpenAlexW2589016211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.